



## PRESS RELEASE

### INFORMATION ABOUT THERAMETRICS HOLDING AG:

- **NEW BOARD OF DIRECTORS OF THERAMETRICS APPOINTED**
- ***BUSINESS COMBINATION* WITH RELIEF THERAPEUTICS SA APPROVED**
- **AGREEMENT WITH ACCELOVANCE EUROPE HOLDING LIMITED UK FOR THE TRANSFER OF SOME SUBSIDIARIES OPERATING IN THE FIELD OF CLINICAL RESEARCH**

Capua, 26 May 2016 – **Pierrel S.p.A.** (“**Pierrel**” or the “**Company**”) informs that, following the termination of the mandate of the Board of Directors, the shareholders meeting of THERAMetrics holding AG, a Swiss company whose shares are listed at the SIX Swiss Exchange and the holding company of the TCRDO Division (“**THERAMetrics**”), met yesterday and appointed the new members of the Board of Directors who, in compliance with the Swiss law, shall be in office until the meeting that shall be called to approve the financial statements as of 31 December 2016.

The composition of the new administrative body of THERAMetrics shall not be an expression of the company anymore. Said circumstance, together with the progressive decrease in the shareholding of the Company in the share capital THERAMetrics that occurred in recent financial years (determining the loss of qualification of the Company as main shareholder of THERAMetrics with a share presently of about 27.4% of the share capital), caused the requirements for the control of Pierrel of the Swiss company to be no longer met. Therefore, dating from today THERAMetrics and the entire TCRDO Division shall be out of the Pierrel Group, in compliance with the directions approved by the Company’s Board of Directors aimed at a further and increasing focus of the Company’s on the manufacturing and commercial *core business*, i.e. *Contract Manufacturing Division*, directly linked to the Company, and *Pharma*, referred to Pierrel Pharma S.r.l., a company wholly owned by Pierrel.

During the same meeting, the shareholders’ meeting of THERAMetrics also approved of the integration with Relief Therapeutics SA (“**Relief**”) already announced to the market (*see* press releases issued by THERAMetrics and Pierrel on 21 December 2015) and the capital increase only for the shareholders of Relief to support the operation. Once finalised the capital increase, to be subscribed by the shareholders of Relief before 30 June 2016 by assigning the 100% of the Relief shares to THERAMetrics, the assignors shall retain the absolute majority of THERAMetrics with a shareholding of some two thirds of the relevant capital, while the share of the Company in THERAMetrics shall be diluted and decrease below 10% of the capital.

Moreover, on the same day THERAMetrics announced to the market that it had signed with Accelovance Europe Holding Limited UK, English company controlled by Accelovance Inc., an American company operating in the clinical research, an agreement to transfer the share capital of four companies controlled by THERAMetrics and working in the field of clinical research. Subject to a customary action for said operations of some conditions precedent, this operation, also announced to the market at the end of the financial years 2015 (*see* press releases issued by THERAMetrics and Pierrel on 21 December 2015) shall imply the *spin off* of the *business* of *Contract Research* from the THERAMetrics group, in compliance with the provision of the corporate plans.

Further information in the press release issued on 25 May 2016 by THERAMetrics available at: [www.therametrics.com](http://www.therametrics.com).



\* \* \*

**Pierrel S.p.A.** is a global supplier to the pharmaceutical industry, specialising in the pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics.

Pierrel has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.

The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

**For further information:**

**Pierrel S.p.A.**

*Investor Relations*

Raffaele Petrone

E-mail: [investor.relations@pierrelgroup.com](mailto:investor.relations@pierrelgroup.com)

tel. +39 0823 626 111

fax +39 0823 626 228

**Global Consult s.r.l.**

*Media Relations*

Rossana Del Forno

E-mail: [areacomunicazione@globalconsultsrl.com](mailto:areacomunicazione@globalconsultsrl.com)

tel. +39 333 6178665